Exact Mass: 840.3429002
Exact Mass Matches: 840.3429002
Found 60 metabolites which its exact mass value is equals to given mass value 840.3429002,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Mebhydrolin napadisylate
Mebhydrolin napadisylate is a specific histamine H1 receptor antagonist.
Albanin H
Albanin H is found in fruits. Albanin H is a constituent of Morus alba (white mulberry). Constituent of Morus alba (white mulberry). Albanin H is found in fruits.
11-Hydroxyaclacinomycin X
C42H52N2O16 (840.3316672000001)
Hexa-His
PGP(i-12:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))
C38H66O16P2 (840.3825896000001)
PGP(i-12:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(i-12:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).
PGP(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-12:0)
C38H66O16P2 (840.3825896000001)
PGP(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-12:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-12:0), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).
kaempferol 3-rhamninoside
sinapyl alcohol 9-O-feruloyl-4-O-alpha-rhamnopyranosyl-(1->2)-alpha-rhamnopyranosyl-(1->2)-beta-glucopyranoside|solargin III
31,32-dihydroxy-82-(1-beta-D-glucopyranosyl)-oxy-1,4,5,10,15,20,22,24-(21H,23H)-octahydro-132-(methoxycarbonyl)-4,5-dioxo-4,5-seco-phytoprophyrinate
methyl 4-[5-[5-[(3-amino-6-methyl-5-oxo-2H-pyran-2-yl)oxy]-4-hydroxy-6-methyloxan-2-yl]oxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1H-tetracene-1-carboxylate
C42H52N2O16 (840.3316672000001)
5alpha-4,5-dihydro-16beta-O-acetyl-scillirosidin-3-O-alpha-L-thevetosido-(1-4)-beta-D-glucoside
Albanin H
Formoterol fumarate
D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents
N,N-di(2-ethylhexyl)-1,7-di(thiophen-2-yl)perylene-3,4,9,10-tetracarboxylic acid bisimide
C48H52N6O4S2 (840.3491272000001)
kaempferol 3-rhamninoside
kaempferol 3-rhamninoside
(3R)-3-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-18-amino-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-15-[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-3-yl]-3-hydroxypropanamide
PGP(i-12:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))
C38H66O16P2 (840.3825896000001)
PGP(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-12:0)
C38H66O16P2 (840.3825896000001)
2-[4-[1,3-Dihydroxy-2-[4-[3-(4-hydroxy-3,5-dimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-6-yl]-2,6-dimethoxyphenoxy]propyl]-2,6-dimethoxyphenoxy]-1-(4-hydroxy-3-methoxyphenyl)propane-1,3-diol
Ferroheme o
C49H60FeN4O5 (840.3912859999999)
A ferroheme having a methyl group at ring position 8 and an isoprenoid chain at position 2.
Mebhydrolin napadisilate
(C19H20N2)2. C10H8O6S2 (840.3015108)
Mebhydrolin napadisylate is a specific histamine H1 receptor antagonist.
methyl (1r,2r,4s)-4-({5-[(5-{[(2r,6s)-3-amino-6-methyl-5-oxo-2,6-dihydropyran-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl)oxy]-4-(dimethylamino)-6-methyloxan-2-yl}oxy)-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylate
C42H52N2O16 (840.3316672000001)
methyl (2r,4s)-4-{[5-({5-[(3-amino-6-methyl-5-oxo-2,6-dihydropyran-2-yl)oxy]-4-hydroxy-6-methyloxan-2-yl}oxy)-4-(dimethylamino)-6-methyloxan-2-yl]oxy}-2-ethyl-2,5,7,12-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylate
C42H52N2O16 (840.3316672000001)
(1s,3s,6s,7e,10e,13r,16r,17s,18s,21r,22s,23e)-17-{[(2r,4r,5s,6r)-5-(3,5-dichloro-1h-pyrrole-2-amido)-4-hydroxy-6-methyloxan-2-yl]oxy}-3,22-diethyl-23-hydroxy-6,18-dimethyl-25,27-dioxo-26-oxapentacyclo[22.2.1.0¹,⁶.0¹³,²².0¹⁶,²¹]heptacosa-4,7,10,14,23-pentaene-4-carboxylic acid
C44H54Cl2N2O10 (840.3155324000002)
2-({[(1s)-1-{[(1r)-2-[(2s)-2-amino-3-(3-hydroxyphenyl)-n-methylpropanamido]-1-({[4-hydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-ylidene]methyl}-c-hydroxycarbonimidoyl)propyl]-c-hydroxycarbonimidoyl}-3-(methylsulfanyl)propyl]-c-hydroxycarbonimidoyl}amino)-3-(3-hydroxyphenyl)propanoic acid
(2e)-3-(4-{[(2s,4s,5s)-3-[(4,5-dihydroxy-6-methyl-3-{[(3s,4s,5s,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl)oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3,5-dimethoxyphenyl)prop-2-en-1-yl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
(4s,7s,13r,22r)-2,5,8,11,14,20-hexahydroxy-22-(hydroxymethyl)-4-(1h-indol-3-ylmethyl)-7-[(4-methoxy-1h-indol-3-yl)methyl]-13,18-dimethyl-16-methylidene-24-thia-3,6,9,12,15,18,21,26-octaazabicyclo[21.2.1]hexacosa-1(25),2,5,8,11,14,20,23(26)-octaen-17-one
C40H44N10O9S (840.3013294000001)
5-(acetyloxy)-3a,3b-dihydroxy-7-[(3-hydroxy-4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-9a,11a-dimethyl-1-(6-oxopyran-3-yl)-dodecahydro-1h-cyclopenta[a]phenanthren-2-yl acetate
(2e)-3-(4-{[(2s,3r,4s,5s,6r)-3-{[(2s,3r,4r,5r,6s)-4,5-dihydroxy-6-methyl-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3,5-dimethoxyphenyl)prop-2-en-1-yl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
17-{[5-(3,5-dichloro-1h-pyrrole-2-amido)-4-hydroxy-6-methyloxan-2-yl]oxy}-3,22-diethyl-23-hydroxy-6,18-dimethyl-25,27-dioxo-26-oxapentacyclo[22.2.1.0¹,⁶.0¹³,²².0¹⁶,²¹]heptacosa-4,7,10,14,23-pentaene-4-carboxylic acid
C44H54Cl2N2O10 (840.3155324000002)
8-[(8s,8ar,12as)-2-(2,4-dihydroxyphenyl)-5-hydroxy-9,9,11-trimethyl-3-(3-methylbut-2-en-1-yl)-4-oxo-8h,8ah,10h,12ah-chromeno[7,8-c]isochromen-8-yl]-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-3-(3-methylbut-2-en-1-yl)chromen-4-one
6-({5-[(2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl)oxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl}oxy)-5-ethenyl-4-{1h,2h,3h,4h,9h-pyrido[3,4-b]indol-1-ylmethyl}-5,6-dihydro-4h-pyran-3-carboxylic acid
C38H52N2O19 (840.3164122000001)
(4s,5r,6s)-6-{[(2s,3r,4r,5s,6r)-5-{[(2r,3r,4s,5r,6r)-2-{[(2s,3s,4r,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-ethenyl-4-[(1s)-1h,2h,3h,4h,9h-pyrido[3,4-b]indol-1-ylmethyl]-5,6-dihydro-4h-pyran-3-carboxylic acid
C38H52N2O19 (840.3164122000001)
(2s)-2-({[(1s)-1-{[(1s,2s)-2-[(2s)-2-amino-3-(3-hydroxyphenyl)-n-methylpropanamido]-1-({[(2z,4r,5r)-4-hydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-ylidene]methyl}-c-hydroxycarbonimidoyl)propyl]-c-hydroxycarbonimidoyl}-3-(methylsulfanyl)propyl]-c-hydroxycarbonimidoyl}amino)-3-(4-hydroxyphenyl)propanoic acid
2-({[1-({2-[2-amino-3-(3-hydroxyphenyl)-n-methylpropanamido]-1-({[(2z,4r,5r)-4-hydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-ylidene]methyl}-c-hydroxycarbonimidoyl)propyl}-c-hydroxycarbonimidoyl)-3-(methylsulfanyl)propyl]-c-hydroxycarbonimidoyl}amino)-3-(3-hydroxyphenyl)propanoic acid
(1r,2s,3ar,3bs,5r,5as,7s,9as,9br,11ar)-5-(acetyloxy)-3a,3b-dihydroxy-7-{[(2r,3s,4s,5s,6s)-3-hydroxy-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-1-(6-oxopyran-3-yl)-dodecahydro-1h-cyclopenta[a]phenanthren-2-yl acetate
8-[(8s,8ar,12ar)-2-(2,4-dihydroxyphenyl)-5-hydroxy-9,9,11-trimethyl-3-(3-methylbut-2-en-1-yl)-4-oxo-8h,8ah,10h,12ah-chromeno[7,8-c]isochromen-8-yl]-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-3-(3-methylbut-2-en-1-yl)chromen-4-one
methyl (1r,2r,4s)-4-{[(2r,4s,5s,6s)-5-{[(2s,4s,5s,6s)-5-{[(2s,6s)-3-amino-6-methyl-5-oxo-2,6-dihydropyran-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-(dimethylamino)-6-methyloxan-2-yl]oxy}-2-ethyl-2,5,7,12-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylate
C42H52N2O16 (840.3316672000001)
2-(2,4-dihydroxyphenyl)-8-[2-(2,4-dihydroxyphenyl)-5-hydroxy-9,9,11-trimethyl-3-(3-methylbut-2-en-1-yl)-4-oxo-8h,8ah,10h,12ah-chromeno[7,8-c]isochromen-8-yl]-5,7-dihydroxy-3-(3-methylbut-2-en-1-yl)chromen-4-one
5-{[(4-amino-5-hydroxy-4,6-dimethyloxan-2-yl)oxy]methyl}-10-[(2r,4s,5s,6s)-5-{[(2s,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-(dimethylamino)-6-methyloxan-2-yl]-2-(2,3-dihydroxybutan-2-yl)-11-hydroxy-1-oxatetraphene-4,7,12-trione
C43H56N2O15 (840.3680506000001)
(1s,3s,6s,7e,10e,13r,16s,17r,18r,21r,22r)-17-{[(2r,4s,5s,6r)-5-(3,5-dichloro-1h-pyrrole-2-amido)-4-hydroxy-6-methyloxan-2-yl]oxy}-3,22-diethyl-27-hydroxy-6,18-dimethyl-23,25-dioxo-26-oxapentacyclo[22.2.1.0¹,⁶.0¹³,²².0¹⁶,²¹]heptacosa-4,7,10,14,24(27)-pentaene-4-carboxylic acid
C44H54Cl2N2O10 (840.3155324000002)
5-{[(4-amino-5-hydroxy-4,6-dimethyloxan-2-yl)oxy]methyl}-10-{5-[(4,5-dihydroxy-6-methyloxan-2-yl)oxy]-4-(dimethylamino)-6-methyloxan-2-yl}-2-(2,3-dihydroxybutan-2-yl)-11-hydroxy-1-oxatetraphene-4,7,12-trione
C43H56N2O15 (840.3680506000001)
(1s,3s,6s,7e,10e,13r,16s,17s,18s,21r,22r)-17-{[(2r,4r,5s,6r)-5-(3,5-dichloro-1h-pyrrole-2-amido)-4-hydroxy-6-methyloxan-2-yl]oxy}-3,22-diethyl-23-hydroxy-6,18-dimethyl-25,27-dioxo-26-oxapentacyclo[22.2.1.0¹,⁶.0¹³,²².0¹⁶,²¹]heptacosa-4,7,10,14,23-pentaene-4-carboxylic acid
C44H54Cl2N2O10 (840.3155324000002)